ReForm’s technologies decrease viscosity and aggregation, increase stability, offer more convenient administration routes, such as subcutaneous delivery of intravenous biologics and can improve the efficiency of downstream processing functions. We also have developed technologies for surfactant replacement, thermal stabilization of ADC’s and inhibition of protein aggregation. ReForm is developing a proprietary pipeline of its own biobetter, patented formulations: 1) to inhibit aggregation of certain biologics prone to aggregation and; 2) for the potential subcutaneous delivery of certain biologics. Our proprietary, biobetter formulations include highly concentrated, low viscosity versions of IvIg and Infliximab for potential subcutaneous injection along with several other molecules. ReForm currently has three US issued patents and >20 pending applications. ReForm's patent estate can provide new IP for market differentiating biobetter and biosimilar formulations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Biobetter for IvIG and Infliximab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):